News Health

News Health. MILAN, Italy — Two impartial efforts to make use of synthetic intelligence (AI) to foretell the event of early rheumatoid.

Read Newshealth.biz news digest here: view the latest News Health articles and content updates right away or get to their most visited pages. Newshealth.biz is not yet rated by Alexa and its traffic estimate is unavailable. We haven’t detected security issues or inappropriate content on Newshealth.biz and thus you can safely use it. Newshealth.biz is hosted with CloudFlare, Inc. (United States) and its basic language is English.

  • Content verdict: Safe
  • Website availability: Live
  • English language flagLanguage: English
  • Last check:
  • N/A

    Visitors daily
  • N/A

    Pageviews daily
  • N/A

    Google PR
  • N/A

    Alexa rank

Newshealth.biz news digest

  • 4 years

    S. Korea Finds Some Liquid E-Cigarette Products Have Ingredient Linked to Lung I...

    SEOUL (Reuters) – South Korean health authorities have found vitamin E acetate, which may be linked to lung illnesses, in some liquid e-cigarette products made by Juul Labs and KT&G, they said on Thursday, but the two companies denied using the material...

  • 4 years

    MLB Removes Marijuana From ‘Drugs of Abuse’, to Test Major League Players for Op...

    NEW YORK (Reuters) – Major League Baseball (MLB) will remove marijuana from its list of banned substances and players who test positive for opioids, fentanyl, cocaine and synthetic THC under random drug tests will be referred for treatment before being...

  • 4 years

    Biosimilar for Crohn’s Noninferior to Adalimumab

    In patients with moderate or severe active Crohn’s disease, the adalimumab biosimilar BI 695501 (Boehringer Ingelheim) is as safe and effective as adalimumab (Humira, AbbVie), new results from a phase 3 trial suggest.
    This is the first randomized controlled study to compare the biosimilar with adalimumab specifically in Crohn’s patients, opening the door to less-costly treatment options for this group, said lead investigator Stephen Hanauer, MD, from Northwestern...

  • 4 years

    Bristol-Myers wins $752 million in U.S. patent case against Gilead

    FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
    (Reuters) – Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer....

Domain history

Web host: CloudFlare, Inc.
Registrar:
Registrant: REDACTED FOR PRIVACY (Private Person)
Updated: May 17, 2022
Expires: July 10, 2023
Created: July 10, 2017

Whois record

Safety scores

Trustworthiness

N/A

Child safety

N/A